552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Mental Health Special Emphasis Panel; Genomic Parsing of Bipolar Disorder and Schizophrenia: Independent R01's.

Date: August 12, 2008. Time: 12 p.m. to 3 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).

Contact Person: Peter J. Sheridan, PhD, Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6142, MSC 9606, Bethesda, MD 20892, 301–443–1513, psherida@mail.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Institute of Mental Health Special Emphasis Panel; Genomic Parsing of Bipolar Disorder and Schizophrenia: Collaborative R01's.

Date: August 14, 2008.

Time: 11 a.m. to 2 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).

Contact Person: Peter J. Sheridan, PhD, Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6142, MSC 9606, Bethesda, MD 20892, 301–443–1513, psherida@mail.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.242, Mental Health Research Grants; 93.281, Scientist Development Award, Scientist Development Award for Clinicians, and Research Scientist Award; 93.282, Mental Health National Research Service Awards for Research Training, National Institutes of Health, HHS)

Dated: August 8, 2008.

Anna Snouffer,

Deputy Director, Office of Federal Advisory Committee Policy.

[FR Doc. E8–18985 Filed 8–15–08; 8:45 am] BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director, National Institutes of Health; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Recombinant DNA Advisory Committee.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: Recombinant DNA Advisory Committee.

Date: September 9-10, 2008.

Time: September 9, 2008, 1 p.m. to 5:30 p.m.

Agenda: The Recombinant DNA Advisory Committee will review and discuss selected human gene transfer protocols as well as related data management activities. Please check the meeting agenda at http://www4.od.nih.gov/oba/RAC/meeting.htm for more information.

Place: National Institutes of Health, Natcher Building, 45 Center Drive, Rooms E1 & E2, Bethesda, MD 20892.

Time: September 10, 2008, 8:15 a.m. to 4

Agenda: The Recombinant DNA Advisory Committee will review and discuss selected human gene transfer protocols. There will be a discussion of the review process for single subject protocols and a discussion of biosafety containment and practices for recombinant work with non-contemporary strains of influenza and the highly pathogenic avian influenza strain H5N1. http://www.4od.nih.gov/oba/RAC/meeting.htm.

Place: National Institutes of Health, Natcher Building, 45 Center Drive, Rooms E1 & E2, Bethesda, MD 20892.

Contact Person: Jacqueline Corrigan-Curay, JD, MD, Executive Secretary, Recombinant DNA Advisory Committee, Office of Biotechnology Activites, OSP, OD, Rockledge 1, Room 750, Bethesda, MD 20892, 301–435–2151, corrigaja@od.nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: http://www4.od.nih.gov/oba/, where an agenda and any additional information for the meeting will be posted when available.

OMB's "Mandatory Information Requirements for Federal Assistance Program Announcements" (45 FR 39592, June 11, 1980) requires a statement concerning the official government programs contained in the Catalog of Federal Domestic Assistance. Normally NIH lists in its announcements the number and title of affected individual programs for the guidance of the public. Because the guidance in this notice covers virtually every NIH and Federal research program in which DNA recombinant molecule techniques could be used, it has been determined not to be cost effective or in the public interest to attempt to list these programs. Such a list would likely require several additional pages. In addition, NIH could not be certain that every Federal program would be included as many Federal agencies, as well as private organizations, both national and international, have elected to follow the NIH Guidelines. In lieu of the individual program listing, NIH invites readers to direct questions to the information address above about whether individual programs listed in the Catalog of Federal Domestic Assistance are affected.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.99, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS)

Dated: August 8, 2008.

Anna Snouffer,

Deputy Director, Office of Federal Advisory Committee Policy.

[FR Doc. E8–18875 Filed 8–15–08; 8:45 am] BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Agency Information Collection Activities: Submission for OMB Review; Comment Request

Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a summary of information collection requests under OMB review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these documents, call the SAMHSA Reports Clearance Officer on (240) 276–1243.

Project: The Coordinating Center to Support State Incentive Grants to Build

Capacity for Alternatives to Restraint and Seclusion (OMB No. 0930-0271)-Revision

The Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Mental Health Services has funded a Data Collection and Analysis for the Alternatives to Restraint and Seclusion Grant Program. This contract is an evaluation of SAMHSA's State Incentive Grants to Build Capacity for Alternatives to Restraint and Seclusion. These grants are designed to promote the implementation and evaluation of best practice approaches to reducing the use of restraint and seclusion in mental health facilities. Grantees consist of 8 sites (state mental health agencies), all of which will be implementing interventions in multiple facilities (a

total of 21 facilities). These include facilities serving adults and those serving children and/or adolescents, with various subgroups such as forensic and sexual offender populations.

With input from multiple experts in the field of restraint and seclusion and alternatives to restraint and seclusion. the project created a common core of data collection instruments that will be used for this cross-site project. The facilities will complete three different instruments over a 3-year time period: (1) Facility/Program Characteristics Inventory (information about type of facilities, characteristics of persons served, staffing patterns, and unit specific data); (2) Inventory of Seclusion and Restraint Reduction Interventions; (3) Seclusion and Restraint Event Data Matrix (data about restraint and

seclusion rates within facilities and units). Data will be submitted by the sites electronically via a secured Web

The Facility/Program Characteristics Inventory and Inventory of Seclusion and Restraint Reduction Intervention will be collected annually. The Seclusion and Restraint Event Data Matrix will be collected monthly.

The resulting data will help to identify the: (1) Number of programs adopting best practices involving alternative approaches to restraint and seclusion; and (2) program's impact of reducing restraint and seclusion use and adoption of alternative practices. The estimated maximal annual response burden to collect this information is by grant vear.

TABLE 1. ESTIMATES OF MAXIMAL ANNUALIZED HOUR BURDEN, BY GRANT YEAR

Instrument	No. of respondents	Responses per respondent	Total responses	Average hours per response	Total annual burden (hours)
Grant Year 1					
Facility/Program Characteristic Inventory	21	1	21	2	42
tions	21 1 21 8 168 Not given during Year 1				
Total Annual	21				210
Grant Year 2					
Facility/Program Characteristic Inventory	Not given during Year 2				
tions	21 21	1 29	21 609	8 8	168 4,872
Total Annual	21				5,040
Grant Year 3					
Facility/Program Characteristic InventoryInventory of Restraint and Seclusion Reduction Interven-	Not given during Year 3				
tions	21	2	42	8	336
Seclusion and Restraint Event Data Matrix	21	18	378	8	3,024
Total Annual	21				3,360

^aThis instrument may be given during Year 1 pending timely OMB approval. If this is the case, some of the responses allotted to Year 2 may be shifted to Year 1 in order to lessen the burden to respondent burden.

Written comments and recommendations concerning the proposed information collection should be sent by September 17, 2008 to: SAMHSA Desk Officer, Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, Washington, DC 20503; due to potential delays in OMB's receipt and processing of mail sent through the U.S. Postal Service, respondents are encouraged to submit comments by fax to: 202-395-6974.

Dated: August 11, 2008.

Elaine Parry,

Acting Director, Office of Program Services. [FR Doc. E8-19052 Filed 8-15-08; 8:45 am]

BILLING CODE 4162-20-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Agency Information Collection Activities: Proposed Collection; Comment Request

In compliance with Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 concerning opportunity for public comment on proposed collections of information, the